Tag Archives: ibrutinib

March, 2016

May, 2015

  • 27 May

    AbbVie Completes $21 Billion Acquisition of Pharmacyclics

    AbbVie has completed its $21 billion acquisition of Pharmacyclics, Inc., strengthening its oncology portfolio. The company said that it has completed the acquisition of Pharmacyclics, a leader in the hematological oncology market with its blockbuster drug Imbruvica (ibrutinib). Imbruvica is a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 …

April, 2015

March, 2015